Drug information
asuptegravir.m4a
| asuptegravir.m4a |
C22 H21 F2 N3 O5
(3S,7R)-N-[(2,4-difluorophenyl)methyl]-11-hydroxy-7-methyl-9,12-dioxospiro[4-oxa-1,8-diazatricyclo[8.4.0.03,8]tetradeca-10,13-diene-6,1'-cyclopropane]-13-carboxamide
Asuptegravir is in Phase 3 development for HIV treatment.
asuptegravir
Molecular Weight: 445.4 g/mol
(Compound details obtained from PubChem,1 Viruses article,2 Aidea Pharma website,3 and ClinicalTrials.gov4)
Pharmacology
Mechanism of Action
Integrase strand transfer inhibitor (INSTI). Asuptegravir is a novel next-generation INSTI with potent in vitro antiviral activity comparable to the second-generation INSTI dolutegravir (DTG). An in vitro selection study indicates asuptegravir has a resistance profile that is differentiated from first- and second-generation INSTIs and may retain activity against certain HIV strains that are resistant to approved INSTIs. As an INSTI, asuptegravir inhibits HIV replication by blocking viral DNA integration into the host genome.2,5
Half-life (T½)
In a Phase 1a study (NCT06278389) evaluating single doses of asuptegravir (5 to 120 mg) in healthy adults without HIV, the mean terminal half-life of asuptegravir was 10.5 to 13.1 hours.6,7
Metabolism/Elimination
Asuptegravir is metabolized by the UGT1A1 enzyme.8
Select Clinical Trials Select Clinical Trials
Select Clinical Trials
Study Identifier: NCT06719310
Sponsor: Jiangsu Aidea Pharmaceutical Group Co., Ltd.
Phase: 1b/2a
Status: This study has been completed.
Study Purpose: The purpose of this study was to evaluate the safety, tolerability, pharmacokinetics, and antiviral effect of asuptegravir as monotherapy and in combination with emtricitabine/tenofovir alafenamide in treatment-naive adults.
Study Population:
- Participants were treatment-naive adults with HIV.
- Participants had HIV RNA ≥5,000 copies/mL at screening and CD4 counts >200 cells/mm3.9
Selected Study Results: Results were presented at the International Workshop on Clinical Pharmacology of HIV, Hepatitis and Other Antiviral Drugs (2025) and showed that once-daily asuptegravir had potent antiviral activity and an adverse event (AE) profile similar to placebo. During the monotherapy phase of the study, asuptegravir (at all doses studied) led to significant reductions in viral load at Day 11 compared with placebo. During the combination therapy phase of the study, approximately 86% of the participants achieved viral load levels of less than 50 copies/mL at Day 29.5
Study Identifier: NCT07711210
Sponsor: Jiangsu Aidea Pharmaceutical Group Co., Ltd.
Phase: 1/2
Status: This study is currently ongoing, but not recruiting participants.
Study Purpose: The purpose of this study is to evaluate the safety and efficacy of an asuptegravir-based antiretroviral regimen in treatment-experienced adults with HIV-1 that is resistant to non-nucleoside reverse transcriptase inhibitors (NNRTIs).
Study Population:
- Participants are treatment-experienced adults with HIV who have been receiving a first-line antiretroviral treatment regimen (one NNRTI plus two nucleoside reverse transcriptase inhibitors [NRTIs]) for at least 6 months.
- Participants have no prior use of INSTIs, protease inhibitors (PIs), or other novel antiretroviral drugs.
- Participants have either HIV RNA ≥400 copies/mL within 8 weeks before screening and ≥400 copies/mL at screening, or HIV RNA ≥50 copies/mL to <400 copies/mL within 8 weeks before screening and HIV RNA ≥1,000 copies/mL at screening.
- Participants have HIV with documented NNRTI resistance mutations and have at least one fully active NRTI backbone drug available which can be used as part of an optimized background regimen.10
Study Identifier: NCT07711223
Sponsor: Jiangsu Aidea Pharmaceutical Group Co., Ltd.
Phase: 3
Status: This study is currently recruiting participants.
Study Population: The purpose of this non-inferiority study is to evaluate the safety and efficacy of asuptegravir in combination with emtricitabine/tenofovir alafenamide in treatment-naive adults. Dolutegravir plus emtricitabine/tenofovir alafenamide will be used as an active comparator.
- Participants are treatment-naive adults with HIV.
- Participants have HIV RNA ≥500 copies/mL at screening.4
Additional early-phase trials evaluating asuptegravir for HIV treatment have been completed, including a Phase 1a study (NCT06278389) that evaluated various properties of asuptegravir in healthy adults, including pharmacokinetics, safety, tolerability, food effects, and drug-drug interactions. The NCT06278389 study has been completed, and results were presented at the International Workshop on Clinical Pharmacology of HIV, Hepatitis and Other Antiviral Drugs 2025 (Abstract 32 and Abstract 33) and ESCMID Global 2026 (Abstract P5206).6
Adverse Events
NCT06719310
In this Phase 1b/2a trial, 36 treatment-naive adults received once-daily asuptegravir (5, 40, or 80 mg) monotherapy or placebo over 10 days, followed by their assigned asuptegravir dose in combination with emtricitabine/tenofovir alafenamide for 18 days. Asuptegravir was reported as being well tolerated, with an AE profile comparable to placebo. None of the participants discontinued asuptegravir because of AEs.5,9
Drug Interactions Drug Interactions
Drug Interactions
A Phase 1a study (NCT06278389) evaluated drug-drug interactions following coadministration of asuptegravir 40 mg with emtricitabine/tenofovir alafenamide. Results indicate that emtricitabine/tenofovir alafenamide has no significant impact on the pharmacokinetics of asuptegravir.6,8
References
- National Center for Biotechnology Information. PubChem compound summary for CID 169913872, asuptegravir. Accessed October 15, 2026
- Ma MD, Luo RH, Li CY, et al. Anti-HIV-1 activity of the integrase strand transfer inhibitor ACC017. Viruses. 2025;18(1):33. doi:10.3390/v18010033. Accessed October 15, 2026
- Aidea Pharma website. Product pipeline. Accessed October 15, 2026
- Jiangsu Aidea Pharmaceutical Group Co., Ltd. A multicenter, randomized, double-blind, double-dummy, dolutegravir sodium tablets controlled, Phase III study to evaluate the efficacy and safety of ACC017 tablets in treatment-naïve adults with human immunodeficiency virus type 1 (HIV-1). In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on July 7, 2026. NLM Identifier: NCT07711223. Accessed October 15, 2026
- Han N, Yang D, Wu L, et al. Antiviral activity, safety and PK/PD of ACC017 in antiretroviral naïve HIV-infected adults: a randomized, double-blind, placebo/dose-parallel-controlled short-term monotherapy study. Br J Clin Pharmacol. 2025;91(S1):16-16. doi:10.1002/bcp.70222. Accessed October 15, 2026
- Jiangsu Aidea Pharmaceutical Group Co., Ltd. Study of single ascending dose, food effects and drug-drug interactions of ACC017 tablets in healthy adult participants in China: a single-center, randomized, double-blind, placebo-controlled, two-stage trial. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on January 23, 2024. NLM Identifier: NCT06278389. Accessed October 15, 2026
- Hu C, Li Y, Zhou Y, et al. Single-dose pharmacokinetics and safety of ACC017, a novel HIV integrase inhibitor, in healthy adult participants: a first-in-human study. Br J Clin Pharmacol. 2025;91:24-25. doi:10.1002/bcp.70237. Accessed October 15, 2026
- Jie Z. Pharmacokinetics, predicted antiviral activity, and safety of single-ascending-dose asuptegravir, a new-generation integrase strand transfer inhibitor, in healthy adults: a two-period, randomised, placebo-controlled phase I study. Abstract presented at: Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global); April 17-21, 2026; Munich, Germany. Abstract P5206. Accessed October 15, 2026
- Jiangsu Aidea Pharmaceutical Group Co., Ltd. A Phase Ib/IIa, randomized, double blinded, perallel, dosing ranging, placebo controled and proof of concept clinical trial to evaluate the safety, tolerability, PK and antiviral effect of ACC017 tablet as monotherapy/combination with NRTI in treatment naïve HIV-infected adults. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on November 26, 2024. NLM Identifier: NCT06719310. Accessed October 15, 2026
- Jiangsu Aidea Pharmaceutical Group Co., Ltd. Efficacy and safety of the ACC017-based antiretroviral regimen in treatment-experienced adults with HIV-1 harboring non-nucleoside reverse transcriptase inhibitor resistance mutations: a randomized, double-blind, placebo-controlled clinical trial. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on July 7, 2026. NLM Identifier: NCT07711210. Accessed October 15, 2026
Last Reviewed: October 15, 2026